103 related articles for article (PubMed ID: 24638849)
21. Publishing clinical research: ten pearls for oncology trainees and junior oncologists.
Mazzarello S; Clemons M; Jacobs C; Arnaout A; Fralick M
Curr Oncol; 2015 Feb; 22(1):e1-5. PubMed ID: 25684991
[No Abstract] [Full Text] [Related]
22. Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases.
Addison CL; Pond GR; Zhao H; Mazzarello S; Vandermeer L; Goldstein R; Amir E; Clemons M
Springerplus; 2014; 3():577. PubMed ID: 25332877
[TBL] [Abstract][Full Text] [Related]
23. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
24. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
25. A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.
Addison CL; Bouganim N; Hilton J; Vandermeer L; Dent S; Amir E; Hopkins S; Kuchuk I; Segal R; Song X; Gertler S; Mazzarello S; Dranitsaris G; Ooi D; Pond G; Clemons M
Breast Cancer Res Treat; 2014 Apr; 144(3):615-24. PubMed ID: 24638849
[TBL] [Abstract][Full Text] [Related]
26. Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer.
Amir E; Freedman O; Carlsson L; Dranitsaris G; Tomlinson G; Laupacis A; Tannock IF; Clemons M
Am J Clin Oncol; 2013 Oct; 36(5):436-42. PubMed ID: 22781385
[TBL] [Abstract][Full Text] [Related]
27. Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer.
Hilton JF; Clemons M; Pond G; Zhao H; Mazzarello S; Vandermeer L; Addison CL
J Bone Oncol; 2018 Mar; 10():6-13. PubMed ID: 29204337
[TBL] [Abstract][Full Text] [Related]
28. A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy.
Clemons M; Dranitsaris G; Ooi W; Cole DE
Breast Cancer Res Treat; 2008 Mar; 108(1):79-85. PubMed ID: 17473981
[TBL] [Abstract][Full Text] [Related]
29. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
[TBL] [Abstract][Full Text] [Related]
31. A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer.
Hutton B; Addison CL; Campbell K; Fergusson D; Mazarello S; Clemons M
J Bone Oncol; 2013 Sep; 2(3):123-31. PubMed ID: 26909282
[TBL] [Abstract][Full Text] [Related]
32. Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient survey.
Hutton B; Morretto P; Emmenegger U; Mazzarello S; Kuchuk I; Addison CL; Crawley F; Canil C; Malone S; Berry S; Fergusson D; Clemons M
J Bone Oncol; 2013 Sep; 2(3):105-9. PubMed ID: 26909279
[TBL] [Abstract][Full Text] [Related]
33. De-escalated administration of bone-targeted agents in patients with breast and prostate cancer-A survey of Canadian oncologists.
Hutton B; Addison C; Mazzarello S; Joy AA; Bouganim N; Fergusson D; Clemons M
J Bone Oncol; 2013 Jun; 2(2):77-83. PubMed ID: 26909274
[TBL] [Abstract][Full Text] [Related]
34. Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial.
Banys M; Solomayer EF; Gebauer G; Janni W; Krawczyk N; Lueck HJ; Becker S; Huober J; Kraemer B; Wackwitz B; Hirnle P; Wallwiener D; Fehm T
BMC Cancer; 2013 Oct; 13():480. PubMed ID: 24128322
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial.
Amadori D; Aglietta M; Alessi B; Gianni L; Ibrahim T; Farina G; Gaion F; Bertoldo F; Santini D; Rondena R; Bogani P; Ripamonti CI
Lancet Oncol; 2013 Jun; 14(7):663-70. PubMed ID: 23684411
[TBL] [Abstract][Full Text] [Related]
36. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer.
Dean-Colomb W; Hess KR; Young E; Gornet TG; Handy BC; Moulder SL; Ibrahim N; Pusztai L; Booser D; Valero V; Hortobagyi GN; Esteva FJ
Breast Cancer Res Treat; 2013 Jan; 137(2):631-6. PubMed ID: 23242617
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]